QUOTED. Aug. 13, 2018. Jonathan Phillips.
When it comes to opioids and enforcement, the US Department of Justice is largely focused on the drug side. But Gibson Dunn attorney Jonathan Phillips says that doesn’t mean device-makers should be complacent about opioid enforcement activities. See what he said here.
"The government activity in that space shows how, when it is looking to further a policy interest that it considers particularly important, it can direct the full extent of its enforcement capabilities to bear. It's so broad now: It's civil, it's criminal, it's federal, it's state, it's False Claims Act, it's multi-district litigation, and then they're going over not only the manufacturers, but also pharmacies that are dispensing opioids, physicians who are prescribing opioids, and anyone who might Jonathan Phillips, attorney, Gibson Dunn
Click here for a free trial of Medtech Insight